IRIDEX Corporation — Q3 2016 Form 10-Q
Business and period. IRIDEX develops, manufactures, and markets ophthalmic therapeutic laser systems, delivery devices, consumables, and services. It reports one segment, ophthalmology. The quarter ended October 1, 2016, and comprised 13 weeks; comparisons are with the 13 weeks ended October 3, 2015. Unless noted otherwise, financial amounts below are in U.S. dollars.
Key financial results
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Revenue | $9.789m | $9.815m | $33.628m | $29.644m |
| Gross profit / margin | $4.245m / 43.4% | $4.841m / 49.3% | $15.276m / 45.4% | $14.468m / 48.8% |
| Operating income (loss) | $(1.247)m | $0.143m | $(1.489)m | $(0.201)m |
| Net income (loss) | $(0.671)m | $0.442m | $(0.898)m | $0.036m |
| Basic and diluted EPS | $(0.07) | $0.04 | $(0.09) | $0.00 |
- Cash and liquidity: Cash and equivalents were $9.577m at October 1, 2016, versus $9.995m at January 2, 2016. Working capital was $23.9m; current assets were $31.406m and current liabilities $7.543m.
- Cash flows, nine months: Operating activities provided $0.195m, investing activities used $1.105m (including $0.792m capital expenditures and $0.313m earn-out payments), and financing activities provided $0.492m. Cash declined $0.418m.
- Debt: No interest-bearing debt was outstanding at October 1. On November 2, 2016, the company entered an undrawn, secured revolving facility of up to $15m, subject to an accounts-receivable borrowing base. Interest is prime plus 1.5%; maturity is November 2, 2019, with no financial covenants.
- Balance sheet: Total assets were $42.714m, total liabilities $8.162m, and stockholders’ equity $34.552m. Inventory was $12.678m.
Material changes versus prior comparable periods
- Q3 revenue was nearly flat year over year. Domestic and international retina-system sales declined, partly due to a shipment-rate issue that management said had been resolved. Higher Cyclo G6 system sales and recurring revenue, particularly MP3 probes, offset the decline.
- Nine-month revenue increased 13.4%, primarily from Cyclo G6 systems and related MP3 probe sales. Systems revenue rose in both domestic and international markets, while recurring revenue grew 11.0%.
- Gross margin fell 5.9 percentage points in Q3 and 3.4 points for the nine-month period. Management cited lower direct margins and manufacturing variances; Q3 also reflected higher manufacturing overhead spending.
- Operating expenses rose 16.9% in Q3 and 14.3% for the nine-month period. General and administrative expense increased substantially, driven by stock compensation and legal expense in Q3, and termination/severance costs, stock compensation, and consulting over nine months.
- Q3 results included a $0.627m income-tax benefit; the nine-month tax benefit was $0.674m. Other expense included remeasurement of acquisition-related earn-out liabilities.
Outlook, commentary, risks, and unusual items
- Management stated that cash, expected operating cash generation, potential capital raising, and access to the new revolver should provide sufficient liquidity for the next 12 months. The filing gives no specific revenue or earnings guidance.
- Management cautioned that gross margins may fluctuate with sales geography and product mix, new products, volume, and manufacturing efficiency. It also highlighted quarter-to-quarter volatility, seasonality, and the possibility of shipment delays.
- Manufacturing, quality, supply-chain, and sales-force training issues had affected shipments of certain products; management said the Q3 issue had been resolved. The filing warns that similar disruptions could recur and harm sales, costs, or product acceptance.
- During the nine months, accelerated vesting of certain restricted stock units following an early termination resulted in a $0.220m G&A charge. Stock-based compensation expense rose to $1.270m from $0.725m.
- Commitments included $2.468m of operating lease payments and $7.901m of purchase commitments, totaling $10.369m. The company reported no material off-balance-sheet arrangements and said ordinary-course legal matters were not expected to have a material adverse effect.
- Key risks include product quality and manufacturing execution, international sales and distributor dependence, competition, regulatory approvals and compliance, reimbursement changes, supplier concentration, and reliance on successful product development. The U.S. dollar’s strength may make products more expensive abroad, although international revenue and costs in the reported period were not denominated in foreign currencies.
- Disclosure controls were assessed as effective at the reasonable-assurance level; the company reported no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Whether the reported shipment and production issues were fully resolved and whether they recur.
- Whether Cyclo G6 and related recurring-probe growth can offset weaker retina-system sales, and what that mix means for gross margin.
- Whether the increases in G&A expense, stock compensation, and severance-related costs persist.
- Whether operating cash generation improves enough to support inventory, capital spending, purchase commitments, and other obligations; the $15m facility is borrowing-base limited and was undrawn when disclosed.
- Whether the tax benefit, deferred tax asset assumptions, and acquisition earn-out remeasurement materially affect future reported results.